EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 40 / No 3 (Mars 2024) Med Sci (Paris), 40 3 (2024) 308-310 References
Issue
Med Sci (Paris)
Volume 40, Number 3, Mars 2024
Nos jeunes pousses ont du talent !
Page(s) 308 - 310
Section Partenariat médecine/sciences - Écoles doctorales - Masters
DOI https://doi.org/10.1051/medsci/2024021
Published online 22 March 2024
  1. Papasotiriou EC, Abdeljelil RB, Benhammou I, et al. Le mélanome uvéal est-il identique au mélanome cutané ? Med Sci (Paris) 2022; 38 : 729–32. [Google Scholar]
  2. Gandini S, Sera F, Cattaruzza M, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005 ; 41 : 45–60. [CrossRef] [Google Scholar]
  3. Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med 2012 ; 10 : 1–9. [CrossRef] [PubMed] [Google Scholar]
  4. Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014 ; 4 : 80–93. [CrossRef] [PubMed] [Google Scholar]
  5. Fourneaux C, Dubois B. Mélanome métastatique-Contribution des lymphocytes B à l’acquisition d’une résistance aux thérapies ciblées. Med Sci (Paris) 2018 ; 34 : 875–878. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009 ; 458 : 438–444. [CrossRef] [PubMed] [Google Scholar]
  7. Soysouvanh F, Giuliano S, Habel N, et al. An update on the role of ubiquitination in melanoma development and therapies. J Clin Med 2021; 10 : 1133. [CrossRef] [PubMed] [Google Scholar]
  8. Wang P, Li Y, Ma Y, et al. Comprehensive investigation into the role of ubiquitin-conjugating Enzyme E2S in melanoma development. J Invest Dermatol 2021; 141 : 374–84. [CrossRef] [PubMed] [Google Scholar]
  9. Montagnani V, Maresca L, Apollo A, et al. E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis. J Biol Chem 2020; 295 : 16058–71. [CrossRef] [PubMed] [Google Scholar]
  10. Habel N, El-Hachem N, Soysouvanh F, et al. FBXO32 links ubiquitination to epigenetic reprograming of melanoma cells. Cell Death Differ 2021; 28 : 1837–48. [CrossRef] [PubMed] [Google Scholar]
  11. Bielskiene. K, Bagdoniene. L, Mozuraitiene, J, et al. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma. Medicina (Kaunas, Lithuania) 2015; 51 : 1–9. [CrossRef] [PubMed] [Google Scholar]
  12. Turcu FER, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 2009 ; 78 : 363–397. [CrossRef] [PubMed] [Google Scholar]
  13. Massoumi R, Kuphal S, Hellerbrand C. et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 2009; 206 : 221–32. [CrossRef] [PubMed] [Google Scholar]
  14. Guo W, Ma J, Pei T, et al. Up-regulated deubiquitnase USP4 plays an oncogenic role in melanoma. J Cell Mol Med 2018 ; 22 : 2944–2954. [CrossRef] [PubMed] [Google Scholar]
  15. Liao Y, Zhou D, Wang P, et al. Ubiquitin specific peptidase 11 as a novel therapeutic target for cancer management. Cell Death Discov 2022; 8 : 292. [CrossRef] [PubMed] [Google Scholar]
  16. Hosseini SM, Okoye I, Chaleshtari MG, et al. E2 ubiquitin-conjugating enzymes in cancer: Implications for immunotherapeutic interventions. Clin Chim Acta 2019 ; 498 : 126–134. [CrossRef] [PubMed] [Google Scholar]
  17. Azuaga Moreso M, Bertrand C, Duffrene J, et al. La technologie PROTAC : une approche thérapeutique prometteuse en oncologie. Med Sci (Paris) 2024; 40 : ce numéro. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.